Recombinant Human TYK2 Protein (556-1187), N-DYKDDDDK-tagged

• Cat.No.: TYK2-02H
• Product Overview: Human TYK2, catalytic/pseudo-kinase domain [556-1187(end) amino acids of accession number NP_003322.3] was expressed as N-terminal DYKDDDDK tagged, biotinylated protein (76 kDa) using baculovirus expression system. The protein was purified by using DYKDDDDK tag antibody agarose.

Specification

• Description: This gene encodes a member of the tyrosine kinase and, more specifically, the Janus kinases (JAKs) protein families. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also a component of both the type I and type III interferon signaling pathways. As such, it may play a role in anti-viral immunity. A mutation in this gene has been associated with Immunodeficiency 35.
• Source: Insect cells
• Species: Human
• Tag: Flag
• Molecular Mass: 76 kDa
• Protein Length: 556-1187
• Purity: 85%
• Storage: Store at -80 centigrade.
  Avoid repeating freeze-thaws.
• Storage Buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5

Gene Information

• Gene Name: TYK2 tyrosine kinase 2 [ Homo sapiens (human) ]
• Official Symbol: TYK2
• Synonyms: TYK2; tyrosine kinase 2; JTK1; IMD35; non-receptor tyrosine-protein kinase TYK2; EC 2.7.10.2
• Gene ID: 7297
• mRNA Refseq: NM_003331
• Protein Refseq: NP_003322
• MIM: 176941
• UniProt ID: P29597

Reviews

10/14/2022

Their expertise in protein production and purification ensures the delivery of a high-quality product that consistently performs well in my experiments.

06/15/2022

They are readily available to address any concerns or questions and supply valuable resources to assist in experimental design and optimization.

01/24/2018

Should I encounter any challenges or require technical assistance, the manufacturer provides prompt and knowledgeable support.

Q&As

Could TYK2 inhibitors have applications beyond autoimmune diseases?

Yes, TYK2 inhibitors might have potential in treating certain cancers and possibly other inflammatory conditions beyond autoimmune diseases.

What are the potential benefits of targeting TYK2 in treating autoimmune diseases?

TYK2 inhibition can potentially reduce inflammation and modulate immune responses without suppressing the entire immune system, unlike some other treatments.

Are there any clinical trials ongoing or completed regarding TYK2 inhibitors?

Yes, there are several clinical trials evaluating the efficacy and safety of TYK2 inhibitors in various autoimmune diseases.

How do TYK2 inhibitors differ from other treatments for autoimmune diseases?

TYK2 inhibitors are more targeted, aiming to interfere with specific signaling pathways involved in the immune response compared to broad immunosuppressants.

How are TYK2 inhibitors administered to patients?

Depending on the formulation, TYK2 inhibitors can be administered orally or through injections.